Drug intelligence / Profile preview

two-component acellular pertussis vaccine

Development stage: Discontinued
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The two-component acellular pertussis vaccine is an investigational biologic vaccine developed by SmithKline Beecham (now GSK) for the prevention of pertussis (whooping cough). It contains two purified antigens from *Bordetella pertussis*: 25 μg of pertussis toxin (PT) inactivated by glutaraldehyde and formalin, and 25 μg of formalin-treated filamentous hemagglutinin (FHA). Typically formulated as a diphtheria-tetanus-acellular pertussis (DTaP) combination, it was evaluated in large-scale clinical trials in Sweden during the 1990s. Although it demonstrated a protective efficacy of 58.9% against laboratory-confirmed pertussis, it was found to be less effective than five-component acellular vaccines and was never commercialized for clinical use.

Other names: SKB acellular pertussis vaccineSmithKline Beecham two-component acellular pertussis vaccine

Targets

FHA (Filamentous hemagglutinin)

Beyond the preview

Go deeper on two-component acellular pertussis vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on two-component acellular pertussis vaccine.

Explore the full profile